4D Molecular Stock Target Set at $36 by H.C. Wainwright

H.C. Wainwright has reiterated a Buy rating on 4D Molecular Therapies (FDMT), setting a target price of $36. This reflects the firm’s confidence in the company's growth prospects and product pipeline. The reiteration of the Buy rating suggests a positive outlook that could support stock performance. A target price above the current market price may attract investor interest and influence trading decisions.